Drug-Testing Disputes & Workplace Results

How can an independent toxicologist assist with a disputed workplace drug test?

A toxicologist can review whether the reported result is consistent with the method, testing panel, reporting limits, specimen information, and other available evidence. The review may identify questions about confirmation, medication-related explanations, specimen handling, or the way the result has been interpreted.

Scientific review does not begin with an assumption that the laboratory, employee, collector, or employer is wrong. The findings may support the result, identify a limitation or error, or leave a question unresolved because important records or specimens are unavailable.

What is the difference between a screening test and a confirmation test?

Many initial screens use immunoassays, which react to a drug or drug class. These results are presumptive: cross-reactivity or limited sensitivity can produce misleading findings, and a class result may not identify a specific substance.

Confirmation generally uses a more specific method, such as gas or liquid chromatography with mass spectrometry, to identify the targeted drug or metabolite. Some testing begins with a definitive method rather than a separate immunoassay screen.

The review should establish which methods were actually used and what was confirmed. Repeating the same presumptive test is not the same as confirming it with a different, appropriately specific method. Even definitive testing has a defined scope, reporting limits, and quality requirements.

Does a confirmed positive result prove impairment at work?

Not by itself. A confirmed result supports the presence of the reported substance or metabolite in the tested specimen within the method's capabilities. It does not automatically establish misuse, the exact time or amount taken, or impairment during a work shift or incident.

Urine findings in particular should not be treated as a measurement of a person's performance or degree of impairment. Specimen type, collection timing, the substance, relevant observations, and the surrounding circumstances matter.

Whether a result meets an employer's policy or has a particular legal consequence is separate from what the laboratory finding scientifically establishes.

Can medicines, supplements, or other products explain an unexpected result?

Sometimes. A prescribed medicine may account for a genuine finding, while some medicines or other substances can interfere with particular screening assays. A parent drug and its metabolites may also produce a pattern that requires careful interpretation.

An explanation must fit the specific analyte, method, timing, and available documentation; simply naming a medicine or supplement does not establish that it caused the result. Screening cross-reactivity should not be assumed to explain a confirmed finding of a different substance.

Product contents may also matter. For example, a product sold as CBD may contain THC, but the product label alone cannot establish what was consumed or whether it explains a particular result. Review may require additional product or analytical evidence.

Do not stop or change prescribed treatment to address a testing concern without consulting the treating clinician.

Does a negative result prove that no drug was used?

No. A negative result applies to the substances tested, specimen, collection time, method, and reporting thresholds involved. The substance may not have been included in the panel, may no longer be detectable, or may be below the reporting cutoff.

There is no single detection window for every person, substance, specimen, or method. Dose and frequency of use, metabolism, specimen concentration, and test sensitivity can affect detectability. A reporting cutoff is not automatically an impairment threshold.

A negative result is not proof of every possible absence of exposure. It also should not be disregarded without a scientifically supported reason.

Why do specimen identity and chain-of-custody records matter?

The records help establish that the tested specimen is associated with the correct person and document its collection, identification, sealing, transfer, receipt, and handling. Relevant information may include specimen identifiers, dates, signatures, seal condition, and laboratory accession records.

A missing entry or discrepancy warrants assessment of its nature and potential effect. It does not automatically prove substitution, contamination, or an invalid result. Likewise, a complete form does not independently prove that every analytical or interpretive step was correct.

Scientific review can assess the documented problem and its possible consequences. Decisions about admissibility, procedural compliance, or legal remedies depend on the applicable rules and are not established by a paperwork concern alone.

Does a dilute or otherwise unusual urine specimen prove tampering?

No. A dilute classification concerns specimen concentration and must be interpreted using the actual measurements and applicable criteria. Dilution can affect detectability, but the classification alone does not establish deliberate interference.

Dilute, invalid, adulterated, and substituted are different reported categories and should not be treated as interchangeable. The underlying findings, validity-testing methods, specimen circumstances, and any required review procedures matter.

The review should distinguish a laboratory classification from a conclusion about who caused the finding or why. An unusual result should not automatically be equated with intentional misconduct or dismissed as harmless without examining the evidence.

Can another test resolve the dispute?

Sometimes. Additional testing of a retained original or split specimen may address a specific analytical question, depending on the amount and condition of the material, the available methods, and the applicable program's procedures. It does not guarantee a different result or resolve every issue about collection, identity, or interpretation.

A newly collected specimen represents a different point in time. A later negative result does not automatically invalidate an earlier positive result, and differences between specimen types or methods may have legitimate explanations.

Access to records, specimen retention, retesting options, and request deadlines vary. Anyone disputing a result should promptly check the applicable procedures with the responsible testing program, designated reviewer, or counsel rather than assume that a scientific consultation preserves a deadline. Ruby's consultation is not a substitute for making a required request through that process.

What records are useful for reviewing a disputed result?

Relevant materials may include:

• The complete laboratory report, including the specimen type, tested substances, units, cutoffs, collection and reporting dates, and any amended reports.
• Initial screening and confirmation results, methods, quantitative findings when available, and relevant laboratory documentation.
• Collection forms, specimen identifiers, seals and receipt records, chain-of-custody documentation, and relevant handling or storage information.
• Specimen-validity findings, including the underlying measurements and any reported classification.
• Relevant prescriptions, medication and product information, reported exposure history, and the timing of use.
• The timeline and relevant observations for any work shift, incident, or performance concern at issue.
• The applicable testing policy, result notices, and authorized reviewer communications relevant to the scientific question.
• Information about retained or split specimens, retention periods, prior retesting, and any known request deadlines.
• Prior expert assessments and the specific conclusions being disputed.

The records needed depend on the question. Missing documentation or unavailable specimens may limit the review. An independent opinion does not guarantee reversal of an employment decision or a favorable outcome.